iTeos Therapeutics Soars 12.3% on Positive Pre-Market Trading

On April 9, 2025, iTeos Therapeutics saw a significant rise of 12.3% in pre-market trading, indicating a strong start to the day for the biotechnology company.

iTeos Therapeutics, Inc. has recently faced a more negative outlook due to sell signals from both short and long-term moving averages, which could be influencing the market sentiment.

Wells Fargo & Company has adjusted its price target for iTeos Therapeutics, lowering it from $19.00 to $17.00 while maintaining an "overweight" rating for the company. This adjustment reflects the firm's assessment of the company's current and future performance.